Ctrl

K

Methazolamide

Class
Antiglaucoma agents
Subclass
Carbonic anhydrase inhibitors
Substance name
methazolAMIDE
Common formulations
Tablet
Dosage and administration
Adults patients
Treatment of glaucoma
•
50-100 mg PO BID-TID
Indications for use
Labeled indications
Adults
•
Treatment of glaucoma
Safety risks
Contraindications
A history of methazolamide hypersensitivity or carbonic anhydrase inhibitor hypersensitivity
Pre-existing electrolyte imbalance (e.g., hyponatremia, hypokalemia, hyperchloremia), acid/base imbalance (metabolic acidosis, acidemia), or adrenal insufficiency
Severe renal disease
Warnings and precautions
Hepatic encephalopathy
•
Use caution with cirrhosis or hepatic impairment.
Respiratory acidosis
•
Use caution with pulmonary disease.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
•
Use acceptable. No dose adjustment required.
Hepatic impairment
Any severity
•
Do not use.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Consider alternative agents that may be safer.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Unknown frequency
•
Acute liver failure, agranulocytosis, allergic reactions, aplastic anemia, ↓ blood neutrophil count, ↓ platelet count, electrolyte imbalance, hepatic necrosis, ↑ urine glucose, metabolic acidosis, myopia, nephrolithiasis, photosensitivity of skin, pure red cell aplasia, change in taste, confusion, diarrhea, fatigue, hematuria, loss of appetite, malaise, melena, nausea, paresthesia, polyuria, somnolence, tinnitus, vomiting, respiratory failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource